NDC 70121-1755

ALYMSYS

Bevacizumab-maly

ALYMSYS is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Amneal Pharmaceuticals Llc. The primary component is Bevacizumab.

• Product ID: 70121-1755_726e0e6b-e934-4ac7-92f6-72636a8aec48
• NDC: 70121-1755
• Product Type: Human Prescription Drug
• Proprietary Name: ALYMSYS
• Generic Name: Bevacizumab-maly
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2022-04-15
• Marketing Category: BLA /
• Application Number: BLA761231
• Labeler Name: Amneal Pharmaceuticals LLC
• Substance Name: BEVACIZUMAB
• Active Ingredient Strength: 400 mg/16mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 70121-1755-7

10 CARTON in 1 CARTON (70121-1755-7) > 1 VIAL in 1 CARTON (70121-1755-1) > 16 mL in 1 VIAL

• Marketing Start Date: 2022-04-15
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "ALYMSYS" or generic name "Bevacizumab-maly"

NDC	Brand Name	Generic Name
70121-1754	ALYMSYS	bevacizumab-maly
70121-1755	ALYMSYS	bevacizumab-maly